{
  "schemaVersion" : 2,
  "registerId" : "F2016L00262",
  "instrumentNumber" : "21/2016",
  "citation" : "Statement of Principles concerning systemic lupus erythematosus (Reasonable Hypothesis) (No. 21 of 2016)",
  "conditionName" : "systemic lupus erythematosus",
  "effectiveFrom" : "2016-04-04",
  "standardOfProof" : "Reasonable Hypothesis",
  "icdCodes" : [ {
    "version" : "ICD-10-AM",
    "code" : "M32"
  }, {
    "version" : "ICD-10-AM",
    "code" : "L93.1"
  }, {
    "version" : "ICD-10-AM",
    "code" : "L93.2"
  } ],
  "onsetFactors" : [ {
    "paragraph" : "9(1)",
    "text" : "being exposed to sunlight or ultraviolet light at a level sufficient to\r\ninduce erythema at least 24 hours, but not more than 30 days, before\r\nthe clinical onset of systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(2)",
    "text" : "inhaling respirable crystalline silica dust, at the time material\r\ncontaining crystalline silica was being:\r\n(a) produced;\r\n(b) excavated;\r\n(c) drilled, cut or ground; or\r\n(d) used in construction, manufacturing, cleaning or blasting,\r\nfor a cumulative period of at least 2 000 hours before the clinical onset\r\nof systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(3)",
    "text" : "where smoking has not ceased before the clinical onset of systemic\r\nlupus erythematosus, smoking at least ten pack-years of cigarettes, or\r\nthe equivalent thereof in other tobacco products, before the clinical\r\nonset of systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(4)",
    "text" : "being treated with a drug from the specified list of drugs at the time of\r\nthe clinical onset of systemic lupus erythematosus",
    "definedTerms" : [ {
      "term" : "specified list of drugs",
      "definition" : "means:\r\n(a) chlorpromazine;\r\n(b) hydralazine;\r\n(c) isoniazid;\r\n(d) methyldopa;\r\n(e) minocycline;\r\n(f) procainamide;\r\n(g) quinidine; or\r\n(h) tumour necrosis factor-alpha inhibitors.\r\nsystemic lupus erythematosus—see subsection 7(2)."
    } ]
  }, {
    "paragraph" : "9(5)",
    "text" : "being treated with a drug which is associated in the individual with:\r\n(a) the development of the symptoms or signs of systemic lupus\r\nerythematosus during drug therapy;\r\n(b) the cessation of the symptoms or signs of systemic lupus\r\nerythematosus within weeks of discontinuing drug therapy;\r\n(c) an absence of clinical or laboratory evidence of systemic lupus\r\nerythematosus prior to beginning drug therapy; and\r\n(d) the development of serological markers which reduce in titre on\r\ndiscontinuing drug therapy; and\r\nwhere treatment with the drug continued for at least the three days\r\nbefore the clinical onset of systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(6)",
    "text" : "having hormone replacement therapy with an oestrogen for at least the\r\ntwo years before the clinical onset of systemic lupus erythematosus",
    "definedTerms" : [ ]
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "9(7)",
    "text" : "being exposed to sunlight or ultraviolet light at a level sufficient to\r\ninduce erythema at least 24 hours, but not more than 30 days, before\r\nthe clinical worsening of systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(8)",
    "text" : "inhaling respirable crystalline silica dust, at the time material\r\ncontaining crystalline silica was being:\r\n(a) produced;\r\n(b) excavated;\r\n(c) drilled, cut or ground; or\r\n(d) used in construction, manufacturing, cleaning or blasting,\r\nfor a cumulative period of at least 2 000 hours before the clinical\r\nworsening of systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(9)",
    "text" : "where smoking has not ceased before the clinical onset of systemic\r\nlupus erythematosus, smoking at least ten pack-years of cigarettes, or\r\nthe equivalent thereof in other tobacco products, before the clinical\r\nworsening of systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(10)",
    "text" : "being treated with a drug from the specified list of drugs at the time of\r\nthe clinical worsening of systemic lupus erythematosus",
    "definedTerms" : [ {
      "term" : "specified list of drugs",
      "definition" : "means:\r\n(a) chlorpromazine;\r\n(b) hydralazine;\r\n(c) isoniazid;\r\n(d) methyldopa;\r\n(e) minocycline;\r\n(f) procainamide;\r\n(g) quinidine; or\r\n(h) tumour necrosis factor-alpha inhibitors.\r\nsystemic lupus erythematosus—see subsection 7(2)."
    } ]
  }, {
    "paragraph" : "9(11)",
    "text" : "being treated with a drug which is associated in the individual with:\r\n(a) an increase in the symptoms or signs of systemic lupus\r\nerythematosus during drug therapy; and\r\n(b) a decrease in the symptoms or signs of systemic lupus\r\nerythematosus within weeks of discontinuing drug therapy; and\r\nwhere treatment with the drug continued for at least the three days\r\nbefore the clinical worsening of systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(12)",
    "text" : "having a clinically symptomatic bacterial, viral or fungal infection at\r\nthe time of the clinical worsening of systemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(13)",
    "text" : "being pregnant within the six weeks before the clinical worsening of\r\nsystemic lupus erythematosus",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(14)",
    "text" : "inability to obtain appropriate clinical management for systemic lupus\r\nerythematosus",
    "definedTerms" : [ ]
  } ]
}